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Abstract
Background:  Recent technological advances in mass spectrometry pose challenges in
computational mathematics and statistics to process the mass spectral data into predictive models
with clinical and biological significance. We discuss several classification-based approaches to finding
protein biomarker candidates using protein profiles obtained via mass spectrometry, and we assess
their statistical significance. Our overall goal is to implicate peaks that have a high likelihood of being
biologically linked to a given disease state, and thus to narrow the search for biomarker candidates.
Results: Thorough cross-validation studies and randomization tests are performed on a prostate
cancer dataset with over 300 patients, obtained at the Eastern Virginia Medical School using SELDI-
TOF mass spectrometry. We obtain average classification accuracies of 87% on a four-group
classification problem using a two-stage linear SVM-based procedure and just 13 peaks, with other
methods performing comparably.
Conclusions: Modern feature selection and classification methods are powerful techniques for
both the identification of biomarker candidates and the related problem of building predictive
models from protein mass spectrometric profiles. Cross-validation and randomization are essential
tools that must be performed carefully in order not to bias the results unfairly. However, only a
biological validation and identification of the underlying proteins will ultimately confirm the actual
value and power of any computational predictions.
Background
Recent advances in mass spectrometry (MS) technology
are starting to enable high-throughput profiling of the
protein content of complex samples. It is foreseeable that
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MS, coupled with chromatographic separation tech-
niques, might become complementary to microarray
technology on the proteome level. The very dynamic
nature of the proteome, the wide range of abundances, the
general lack of a "protein catalog" (unlike the genomic
catalog, which is all but complete for a number of organ-
isms) and various technical challenges in capturing pro-
teins make this a particularly ambitious and challenging
undertaking. While MS has been used extensively on puri-
fied, digested samples to identify proteins via peptide
mass fingerprints, the data we use in this paper are funda-
mentally different since they consist of mass spectra (or,
more precisely, peaks from mass spectra) of complex mix-
tures such as blood serum. After some chromatographic
separation steps (which are crucially important, but not
the primary subject of this paper), a mass spectrum of the
matrix-crystallized sample is obtained on a wide mass
range (in our case, 2–40 kDa) in order to obtain a profile
of the protein content of a sample. If reproducibility is
ensured, then these spectra can be used to identify peaks
whose intensities correlate with a particular phenotype of
interest, e.g., in this paper, prostate cancer.
The purpose of this paper is to show that computational
methods can be useful in narrowing the search for protein
biomarker candidates. Once we find a small set of peaks
that can be used to computationally "predict" phenotypes
with high accuracy, these peaks should be analyzed fur-
ther and the underlying proteins identified, e.g, by focus-
ing an MS/MS instrument on the relevant peak masses.
The hope is that the subsequent functional study of these
proteins will eventually lead to new biological insights
into disease pathways and, ultimately, to reliable diagnos-
tic tests and potential therapeutic targets. We want to
stress the need for biological validation; the inherent var-
iability of mass spectrometry data makes it uncertain
whether peak profiles can be used for diagnosis directly.
The need for computational methods is evident in order
to find peaks that correlate with phenotypes and, equally
importantly, in order to assess their statistical significance.
We survey several classification (or supervised learning)
methods that can be used in this context and apply them
to a multi-class prostate cancer prediction problem. Given
that sample sizes for these kinds of experiments are typi-
cally small, and given that validation of any results we
produce requires laborious protein identification, our aim
is to find the smallest set of peaks that yields reasonable
(i.e., statistically significant) classification results.
The literature on classification techniques as well as the
related field of machine learning is vast; we will not even
attempt to give a summary but will rather refer the readers
to, e.g., the excellent book by Hastie, Tibshirani and Fried-
man [1]. Several of these methods have been utilized for
discriminating cancer samples from normal (control)
samples using proteomic data. The two main components
of these approaches are 1) the feature selection (dimen-
sion reduction) method and 2) a classification method to
build a predictive model. For example, Petricoin et al. [2]
used genetic algorithms for feature selection and
Kohonen's self-organizing map classification in their
study of ovarian cancer (see also Sorace and Zhan [3] for
a more detailed and principled analysis of the same data).
Li et al. [4] used the signal-to-noise ratio for an initial fea-
ture selection and, subsequently, used "unified maximum
separability analysis" repeatedly for classification in their
breast cancer study. Adam et al. [5] and Qu et al. [6] used
the "area under the Receiver Operating Characteristic
(ROC) curve" criterion for feature selection and decision
trees in conjunction with boosting techniques for classifi-
cation in a prostate cancer study. Lilien et al. [7] analyzed
the same data and the ovarian cancer data from Petricoin
et. al. [2] with a probabilistic algorithm based on princi-
pal components and linear discriminant analyses.
In this paper we contrast the performance of several
selected statistical and optimization-based techniques on
the SELDI-TOF data from Adam et al. [5] and, in contrast
to previous studies, assess their prediction significance via
randomization techniques. These methods were selected
for this study based on their simplicity and their wide-
spread use and availability. While this is far from a com-
prehensive benchmark study, we make several points
about the need for rigorous cross-validation and
randomization.
By dividing the data set at our disposal into training set (to
be used for model building) and test set (to estimate the
generalization power of the model), and by doing this
randomly and many times over, we can benchmark vari-
ous classification methods reliably and gain insights into
their capabilities of handling proteomic data. In particu-
lar, we used Fisher's linear and quadratic discriminant
functions, nonparametric kernels, nearest neighbor meth-
ods and linear support vector machines for classification.
Misclassification rates are biased (downward) when both
the training and test sets are used for feature selection as
opposed to when only the training set is used. While per-
forming the cross-validation studies, care was taken so
that the test set does not influence the choice of the peaks
used in the classification.
Although we will use the above mentioned prostate can-
cer data for illustration, the data analysis strategies and the
methods used here are of general applicability and could
easily be adapted for other mass-spectrometry datasets. In
earlier work [8] we have proposed candidate biomarkers
in lung cancer using protein profiles obtained via MALDI-
TOF (matrix assisted laser desorption and ionization-timeBMC Bioinformatics 2004, 5 http://www.biomedcentral.com/1471-2105/5/26
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of flight) mass spectra (data provided by Duke Univer-
sity's department of Radiology) by employing similar data
analysis strategies and classification methods. One of the
five peaks found to be most useful in classifying lung can-
cer, and the only one up-regulated in cancer, was subse-
quently identified by Howard et. al [9] as stemming from
Serum Amyloid A, an inflammatory marker, which we
take to be an encouraging indication that this kind of
analysis indeed has the potential to reveal relevant
biomarkers.
Results and discussion
In what follows, unless otherwise indicated, the accuracy
we report in the tables consists simply of the fraction of
correctly classified samples, which is reasonable given that
the sizes of the four class sizes are roughly balanced. Also,
unless otherwise indicated, all error rates are computed as
average error rates over 100 runs, that is, a cross-validation
procedure of training on 90% of the data and testing on
the remaining 10% was repeated 100 times and the errors
averaged. Table 1 reports experiments on the original
dataset with samples categorized into four groups: BPH,
early (localized) cancer, late (metastasized) cancer and
controls. Results for the first four classification methods
(quadratic discrimination, nonparametric kernel method,
kNN and Fisher's linear discriminator) reported were
obtained with codes implemented in SAS. Results for the
linear SVM were obtained with the package SvmFu [10].
For kNN we experimented with values of k between 3 and
7 and saw little overall sensitivity to the particular choice
of k. We report results for k = 6. The linear SVM requires
an a-priori choice of a tradeoff parameter C that balances
misclassification and margin maximization. Instead of
fine-tuning each SVM (which is rather computationally
expensive, especially compared to the other four meth-
ods), we tried various discrete values (log C = -3, -2,...,1)
and observed that the best performance was always
achieved with either C = 1 or C = .1. The results we report
in the table correspond to the best of the these runs.
As can be seen in Table 1, the methods achieve rather
comparable prediction accuracies, with the best cross-val-
idated result being obtained in this case by the linear dis-
criminators. These results should be viewed in the context
of what one would expect to see if the peaks considered
contained no information with regard to the various phe-
notypes. Since there are four classes, a random classifier
would be expected to achieve about 25% accuracy. We
also note the rather high standard deviations (shown in
parentheses), which indicate there was a wide range of
observed classification accuracies over the 100 runs
performed.
In order to get a sense of the significance of these results
and to attempt to rule out data artifacts, we checked the
performance of the classifiers on the same data but with
randomized group assignments. We generated 1000 rand-
omized datasets (the labels of the entire dataset were per-
muted at random) and averaged the performance of the
linear SVM using 15 peaks on 10 random choices of test
and training set (so that in fact 10,000 random runs were
performed). The best classification accuracy average out of
those 1000 runs was 34.4%, while the median classifica-
tion accuracy was 24.1%. This is significantly below the
79.3% reported in Table 1 and is an indication that these
results are not merely due to some spurious structure in
the data.
Finally, Table 1 also illustrates that all methods are rather
sensitive to noise. Increasing the number of peaks at times
deteriorates the classification accuracy, underscoring the
need for high-quality feature selection procedures. As
mentioned in the introduction, our aim is to find a small
set of peaks that have good prediction capabilities. The
results presented here are meant to assess the
generalization capabilities of the modeling approach; the
"final" set of peaks can then, of course, be chosen using
the entire set. Conclusions to be drawn from the particular
peaks here are the subject of future research.
Table 1: Cross-validation classification accuracy (in percent) of various classification methods on the full four-class prostate cancer 
dataset using various numbers of peaks. Numbers are average observed accuracies over 100 runs with randomized 90/10 splits into 
training and test sets, respectively. The numbers in parentheses are the corresponding standard deviations.
# of peaks used
10 15 20 25 30 35 50 70
Quadr. Discr. 74.7 (7.4) 74.7 (9.6) 74.1 (8.4) 74.7 (7.1) 78.2 (6.8) 77.8 (7.3) 78.7 (6.6) 76.8 (7.1)
Nonpar 
(Kernel)
76.7 (7.1) 77.4 (8.4) 77.7 (6.9) 78.6 (6.6) 80.0 (6.3) 79.9 (7.3) 78.1 (6.5) 76.1 (7.6)
kNN 73.4 (7.4) 76.4 (6.9) 76.9 (6.0) 76.6 (6.1) 75.8 (6.7) 77.2 (6.9) 73.9 (7.5) 69.8 (6.7)
Fisher Linear 72.4 (7.3) 77.3 (6.9) 80.8 (6.5) 80.1 (5.8) 81.8 (6.0) 84.6 (5.2) 85.5 (6.1) 84.3 (5.1)
Linear SVM 75.4 (6.4) 79.3 (7.4) 81.7 (7.2) 81.3 (5.7) 83.7 (6.8) 83.1 (6.6) 83.5 (6.1) 84.0 (6.2)BMC Bioinformatics 2004, 5 http://www.biomedcentral.com/1471-2105/5/26
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For illustration purposes, we show detailed results
obtained with Fisher's Linear Discriminator using 20
peaks on the full four-class problem in Table 2. We note
that by far the largest source of misclassification comes
from the late cancer group, indicating perhaps that it is a
rather heterogeneous group in nature. In any case, we
want to stress again that our aim is not so much to achieve
perfect classification but rather to gather evidence that at
least some of the underlying peaks are likely to be impli-
cated in the disease. We believe that this goal has been
achieved.
It turns out that we can further reduce the number of
peaks required to classify accurately by considering a two-
stage hierarchical classification procedure. First, we aim to
distinguish whether a sample is benign (control or BPH)
or cancerous. As seen in Table 3, this can be achieved with
high accuracy (91.0%) with only 8 peaks using a linear
SVM. Table 4 shows the average prediction accuracy
achieved on other pairwise discriminations, indicating
that the control versus BPH distinction can be made with
96% accuracy using just 5 peaks. Thus we obtain at least
87% accuracy for the two-stage process with a total of 13
peaks, assuming we do not need to distinguish between
early and late cancers. This procedure also implies an
alternate feature selection strategy for multi-class prob-
lems: Instead of ranking features using the F-statistic crite-
rion on the entire data set, choose the union of top-
ranking features that score highest in pairwise
comparisons.
To assess the significance of these classification results we
sampled from the empirical distribution of misclassifica-
tion rates by randomly permuting the class labels. By per-
forming 1000 randomization runs we can obtain
estimates for the 95th percentile of that empirical error
distribution. A generalization error estimate obtained by
cross-validation on the true data set which is above the
95th percentile of the empirical error distribution can be
interpreted as a confidence certificate. The following table
contains the 95th percentile estimates and the means of
the empirical misclassification error distribution for a
subset of the methods and problems from above.
Table 5 shows that the accuracy rates achieved in Table 4
are far better than any results on randomized data, giving
us additional confidence that the chosen peaks are indeed
significant.
We also want to mention briefly that when all 5 classifica-
tion methods are trained using the entire dataset and 15
peaks, 74% of all samples are correctly classified by all
methods simultaneously. We take this high level of con-
cordance of the classification methods as a strong indica-
tion and additional evidence that a large majority of
samples are indeed well separated in this low-dimen-
Table 2: Details of classification results obtained with Fisher's Linear Discriminator and 20 peaks on the full four-class problem. The 
overall average classification accuracy (100 runs) is 81%.
Computational Prediction
BPH Late Cancer Early Cancer Control
BPH 745 (93.1%) 55 (6.9%) 0 (0%) 0 (0%)
Clinical Late Cancer 156 (19.5%) 531 (66.3%) 91 (16.0%) 22 (1.6%)
Diagnosis Early Cancer 99 (12.3%) 54 (6.8%) 616 (82.0%) 31 (1.8%)
Control 92 (11.5%) 11 (1.4%) 5 (0.6%) 692 (86.5%)
Table 3: Average classification accuracy over 100 runs on data obtained by grouping all control and BPH samples into one class, and all 
cancer samples into another. Class sizes thus remain approximately balanced. Numbers in parentheses are standard deviations.
# of peaks used (malignant vs. other)
5 8 10 12 15
Quadr. Disc. 84.1 (5.3) 85.1 (5.4) 85.0 (6.1) 86.1 (6.7) 86.0 (6.1)
Nonpar. (Kernel) 84.6 (5.2) 87.1 (5.3) 88.3 (5.8) 88.9 (6.1) 88.1 (6.0)
kNN 89.9 (4.6) 87.4 (5.6) 87.5 (5.7) 88.9 (5.2) 88.5 (4.6)
Fisher Linear 88.6 (5.9) 88.4 (5.6) 87.9 (4.9) 89.1 (5.4) 88.0 (5.0)
Linear SVM 89.5 (5.5) 91.0 (4.8) 91.9 (4.6) 91.7 (4.9) 91.9 (4.7)BMC Bioinformatics 2004, 5 http://www.biomedcentral.com/1471-2105/5/26
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sional space, and that there is significant information con-
tent in this dataset which can be used to discriminate
between the four classes.
Finally, we want to mention the top masses that repeat-
edly appear in the peak selection list of various classifiers:
9720.0, 9655.7, 5074.2, 3896.6, 3963.2, 7819.8, 7844.0,
6949.2, 8943.1, 4079.5. Some of these masses, e.g.,
7819.8 and 9655.7, had also been used in previous stud-
ies (Adam et al., [5]) as being important discriminators.
Note, however, that all masses are in the range of those of
typical proteins (unlike those appearing in [2]). While the
identification of the underlying proteins and our under-
standing of their biological significance is still outstand-
ing, we believe that the results we provide here do indeed
indicate that they are good candidates for biomarkers and
that their identification can provide new insights of clini-
cal relevance.
Methods
Samples
Serum samples were obtained from the Virginia Prostate
Center Tissue and Body Fluid Bank. Surface enhanced
laser desorption/ionization time-of-flight (SELDI-TOF)
mass spectrometry protein profiles of serum from 82
unaffected healthy men, 77 patients diagnosed with
benign prostatic hyperplasia (BPH), 84 patients with
organ-confined prostate cancer (PCA), and 83 patients
with non-organ-confined PCA were available, in dupli-
cate, for the analysis. For details on sample preparation
and the particular kind of chromatographic affinity chip
used, see Adam et al. [5]. Each spectrum is an array of
intensities of the signal at discretely sampled values of the
mass-to-charge ratio of the ions.
In contrast to, e.g., Petricoin et. al. [2] our data is preproc-
essed by filtering out intensities that do not correspond to
peaks in any samples since these will likely cloud the true
information content of the spectrum. In order to use the
intensities as indicators of relative abundance of the sup-
posed peptide in the sample, baselines must be subtracted
and the intensities normalized. Furthermore, mass meas-
urement inaccuracies imply that peaks stemming from the
same peptide may occur at different mass locations in
different samples, so peaks must be aligned across sam-
ples. (See [8] for more details).
For the data in this paper, peak detection and alignment
were performed with Ciphergen ProteinChip Software 3.0
with some modifications. All 652 spectra (326 samples in
duplicate) were compiled and 779 peaks in the mass
range from 2 to 40 kDa were selected by the ProteinChip
software for analysis. This range contains the majority of
the resolved protein/peptides [6]. Details of the steps
involved in this pre-processing of the data are given in
Adam et al. [5]. In this analysis, to avoid biasing the fea-
ture selection procedure and/or the cross-validation
Table 4: Linear SVM classification average accuracy results for other pairwise distinctions using varying numbers of peaks.
# of peaks used
5 8 10 12 15
BPH vs Control 96.4 96.2 96.6 96.4 97.4
BPH vs E. Cancer 91.8 94.6 93.6 94.7 95.4
BPH vs L. Cancer 89.1 88.1 88.9 89.7 91.7
Control vs E. Cancer 89.1 91.5 94.4 95.5 96.2
Control vs L. Cancer 88.0 88.7 88.5 90.4 90.0
Table 5: Statistics on classification accuracy for the linear SVM averaged over 1000 randomized datasets. 10 cross-validation runs using 
15 peaks were performed on each dataset.
max. acc. median acc. 95th %ile
BPH vs Control 70.0 51.6 59.7
BPH vs E. Cancer 68.1 50.0 59.4
BPH vs L. Cancer 68.1 50.0 59.7
Control vs E. Cancer 66.9 50.0 59.7
Control vs L. Cancer 65.0 51.6 59.3BMC Bioinformatics 2004, 5 http://www.biomedcentral.com/1471-2105/5/26
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results, we only used the data corresponding to the first
mass spectrum for each sample.
Peak selection
Feature selection, i.e., the reduction of the number of
input variables (or, in our case, peaks), is a crucially
important step. Many classification methods are known
to perform poorly when "irrelevant" features or ones with-
out information content are added. Secondly, computa-
tional biologists are frequently faced with the problem of
having only a few (tens) samples but many (thousands)
descriptors, as is the case with microarray analysis. This
presents the challenge of designing models that are not
"overfitted" to the data. One approach to prevent this is to
try to decrease the dimensionality by performing feature
selection.
In our case, we are interested in finding a reasonably small
set of peaks in order to then enable the identification of
the underlying proteins and, eventually, understand the
biological function they have in the disease pathway. In
this sense the classification methods used can be viewed
as validation methods for the feature selection algorithms.
Unfortunately, finding the "best" set of features to build a
predictive model is a hard combinatorial problem, and so
one must live with heuristic approaches. The literature on
this subject is vast, and one generally distinguishes
between filtering methods (those which rank individual
features according to some criterion) and more involved
wrapper algorithms, which use classification methods
directly to evaluate a particular set of features.
For this paper we use only simple filter methods since they
seem to do reasonably well for our purposes. We first
chose to disregard any peaks appearing in 30 or fewer
samples, thus preventing the classification methods from
taking advantage of what are likely to be spurious peaks or
data artifacts, possibly contaminants. In our particular
case this resulted in a reduction from 779 peaks in the
original dataset to 220. With more than 300 samples at
our disposal we deemed this to be a good starting point.
In order to further reduce the number of features to, say,
under 25, we used the ratio of between group sum of
squares and within group sum of squares (B/W ratio), for
feature selection. Suppose that yikj is the observed intensity
of the jth feature of the kth sample belonging to the ith
group, that the number of groups is denoted by g, that ni
is the number of samples in the ith group, and that
, .  Then  the
between group sum of squares for the jth feature is
 and the within group sum of
squares is  . For every feature
j = 1,...,p we compute Bj/Wj or, equivalently (for ordering
purposes), the ANOVA F-statistic  , where ν1
= g - 1 and   are the degrees of freedom of
Bj and Wj respectively. Then the reduced data set will be
the data corresponding to the q largest Fj values.
Principal Component Analysis (PCA) is another popular
and very general method for reducing the dimension of
the data. Instead of working with the original variables,
only a few selected "principal components," which are
linear combinations of the original variables, are used for
the analysis. Although the principal components have an
advantage of explaining most of the variation in the orig-
inal data, they may not be very useful in the present con-
text where knowing the identity of the masses where the
peaks occur is important. The elements of the eigenvectors
that are used as principal components can, in principle, be
used to select the original variables, but the heuristic and
subjective nature of this approach makes this a less
appealing approach for us in this context. (See Khattree
and Naik [11] for an illustration of this approach and Lil-
ien et al. [7] for an application to prostate cancer data.)
Classification/discrimination methods
The next task is to perform a discriminant analysis to con-
struct discriminant functions so that the classification of
the new unknown samples obtained from MS can be per-
formed. Various classical and modern methods are avail-
able for this purpose. Classical statistical methods
(parametric as well as nonparametric) have stood the test
of time and proved to be very useful. However, two mod-
ern classification methods have emerged recently. One set
of methods is bagging with boosting of classification
trees, and the other set is based on support vector
machines. Boosting methods have been utilized by Qu et
al. [6]. Here we will adopt several classical statistical meth-
ods and support vector machines for our analysis. In the
following we will only briefly mention these methods;
details can be found in Khattree and Naik [11] and Hastie,
Tibshirani, and Friedman [1].
The quadratic discriminant rule is a likelihood-based discri-
minant procedure in which multivariate normal probabil-
ity density functions with unequal variance co-variance
matrices are used. When the form of the probability den-
sity function is not known, the data can be used to esti-
mate the densities. This is generally done using the kernel
y
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method, and we will be referring to this procedure as non-
parametric (kernel) discrimination method.
Fisher's canonical (linear) discriminant analysis provides a
method where no probability density functions are used
directly. Instead, only a few (less than or equal to g - 1)
canonical variables, which are certain linear combina-
tions of the original variables, are employed. The canoni-
cal variables are likely to improve on the discrimination
between the groups than any individual variable because
these are created such that the between group sum of
squares for these variables is larger relative to the within
group sum of squares.
The k-nearest neighbor method (kNN) provides another
approach that is based on distances from 'immediate
neighbors' and hence bypasses the need for a probability
density. Two common distance measures used in this con-
text are (i) the Mahalanobis distance or Euclidean dis-
tance and (ii) one minus the absolute value of the
correlation coefficient between the two samples. In this
method we first compute the affinity measure between the
unknown sample and all known classified samples. Next,
we find the samples corresponding to the k smallest val-
ues of the selected affinity measure, where k is pre-speci-
fied. The unknown sample is classified as belonging to the
group to which the majority of the k  closest samples
Accuracy and standard deviation estimates as a function of the number of cross-validation runs (shown, as an example, for the  Fisher method with 15 peaks) Figure 1
Accuracy and standard deviation estimates as a function of the number of cross-validation runs (shown, as an example, for the 
Fisher method with 15 peaks). Significant variability can be observed at the beginning, which motivates the need for a large 
number of runs in order to arrive at reasonable estimates.BMC Bioinformatics 2004, 5 http://www.biomedcentral.com/1471-2105/5/26
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belong. It is clear that we may have undecided cases in this
approach.
Support vector machines (SVMs) are powerful classification
tools that arose out of the machine learning and optimi-
zation communities in the 1960's (e.g., [12]). SVMs are
large-margin classifiers, that is, they solve an optimization
problem which finds a separating hyperplane that opti-
mizes a weighted combination of the misclassification
rate and the distance of the decision boundary to any sam-
ple vector. The reader is referred, e.g., to Cristianini and
Shawe-Taylor [13] for details. In addition to linear ver-
sions of SVMs, they have been extended to nonlinear cases
via kernels; however, since we did not see any significant
performance improvement on this data using nonlinear
kernels compared to the much simpler linear SVMs (data
not shown), we constrained ourselves to reporting on
experiments with linear SVMs. The extension of SVMs to
the case with multiple classes such as our particular appli-
cation is still an active research topic. Lee, Lin and Wahba
[14] have found natural and theoretically satisfying exten-
sions; however, we have opted for another scheme that is
reasonable for small values of g, which, despite its simplic-
ity, has produced quite satisfactory results in practice. We
opted to adapt the pairwise approach that constructs all
g(g - l)/2 pairwise discriminators for g classes (groups).
The final classifier is taken to be the one that dominates
all others, if one exists. Otherwise the result is considered
to be inconclusive, an event that occurs in only a very
small percentage of cases. We want to point out that even
in the inconclusive cases it is sometimes possible to rule
out certain classes (in case they are dominated by all oth-
ers), which is an outcome that might still be of some clin-
ical relevance.
Cross-validation
In order to assess the generalization power of each of the
classification methods and to estimate their prediction
capabilities for unknown samples, we used a standard
cross-validation technique and split the data randomly
and repeatedly into training and test sets. The training sets
consisted of randomly chosen subsets containing 90% of
each class (for a total of 294 per run); the remaining 10%
of the samples from each class (a total of 32) were left as
test sets. We stress that feature selection was performed in
every experiment on the training set only (unlike what is
often seen in the literature) in order not to bias the feature
selection procedure unfairly. Several papers (including
[8]) have shown that performing feature selection on the
entire dataset often grossly underestimates the true gener-
alization error.
Repeated cross-validation runs can be used to estimate the
average classification accuracy as well as the standard
deviation. However, obtaining reliable estimates (e.g., in
order to compare different classification methods) is
problematic and requires careful consideration. Figure 1
shows the variability of the estimates for mean classifica-
tion accuracy as well as the standard deviation as a func-
tion of the number of cross-validation runs (using, as an
example, Fisher's linear discriminator and 15 peaks). Even
between runs 90 and 100 the estimates for mean error dif-
fer by as much as .4%, which indicates that any reported
accuracies should really only be considered significant to
the second digit. This is not really surprising: we
performed a small simulation where 10,000 samples of
size 100 were drawn from N(13,7), and in 5% of cases the
relative error of the sample mean (standard deviation) to
the true mean (standard deviation) was greater than
10.6% (14.1 %), indicating that the mean and standard
deviation estimates stemming from 100 runs are, in gen-
eral, far from converged.
In order to keep computing times reasonable, we limited
ourselves to reporting accuracy and standard deviation
estimates over 100 runs, but we stress that more runs are
required should more accurate estimates be desired.
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